FDA approves NVS’ Tafinlar+Mekinist for BRAF-V600E NSCLC: https://t.co/SaM4hE3Xhl This is the first FDA-approved “targeted” regimen for BRAF+ NSCLC. The regimen is already approved in the EU for this indication. The companion diagnostic is furnished by TMO (#msg-132421371).